Maple Syrup Urine Disease

Crystal structure of the human mitochondrial branched-chain alpha-ketoacid dehydrogenase, subunit E1 (source: http://www.pdb.org/)

Summary

Maple syrup urine disease (MSUD) is a disorder of the branched chain amino acid (BCAA) catabolism. Due to a deficiency in the branched chain alpha-keto acid dehydrogenase complex (BCKDC) the degradation of leucine, isoleucine and valine is impaired so that these amino acids and the corresponding alpha-keto acids accumulate. Affected infants suffer from mental and physical retardation. MSUD has an autosomal recessive heredity.

Phenotype

Sotolone (source: http://www.ebi.ac.uk/chebi/)

The name of the disease comes from the sweet smell of newbornes urine that resembles maple syrup. The compound sotolone, a metabolite of leucine, is responsible for this smell. BCAAs and alpha-keto acid concentrations in blood plasma are increased which has toxic effects like ketonuria, lethargy, seizures, vomiting, problems in feeding and neurological dysfunctions. As a consequence of this, if untreated the disease leads to coma and in the end to death.

There are different forms of MSUD depending on the proportion of BCKDC enzyme activity that is still present:

• The classic severe neonatale form is the most common form where almost no rest enzyme activity can be measured. The newborns develop severe symptoms 4 to 7 days after birth.
• In the intermediate form there is an enzyme activity of up to 30 %. So the symptoms are less severe than in the classic form.
• The intermittend form has a later onset because there is a partial enzyme activity. Symptoms can appear episodically. A dietary restriction with low BCAA content can be an effective treatment.
• In the thiamine-responsive form there is an enzyme activity of up to 40 %. The serum levels of BCAAs can be normalized with a thiamine therapy because in this form a mutation affects the affinity of a thiamine binding site of the BCKDC.

All of the above mentioned forms can be caused by mutations in the gene of any subunit of the BCKDC.

Another classification divides the disease into subtypes depending on the subunit of the enzyme complex (see #Biochemical disease mechanism) that is altered - type IA/IB/II or III if subunit E1 (alpha chain), E1 (beta chain), E2 or E3 is altered, respectively. In some sources type III is actually considered another disease which is similar to MSUD, called dihydroliponamide dehydrogenase deficiency. The reason is that this subunit is also a part of other enzyme complexes, e. g. the pyruvate dehydrogenase complex.

Cross-references

See also description of this disease in

• Wikipedia
• OMIM
• HGMD: BCKDHA, BCKDHB, DBT, DLD
• PubMed Health
• GeneReviews

Biochemical disease mechanism

The branched chain amino acids leucine, isoleucine and valine (source: http://www.ebi.ac.uk/chebi/)

BCAA degradation (source: KEGG) highlighting disease associated enzymes

The first step in degradation of the BCAAs leucine, isoleucine and valine is the oxidation to branched chain alpha-keto acids (BCKAs). This reaction is catalyzed by cytosolic branched-chain amino-acid aminotransferase which cuts off the α-amino group of the BCAAs and substitutes the chemical group with a carbonyl group. This process takes part in the cytosol of cells. The produced α-keto acids are then transported into mitochondria and decarboxylated by the BCKDC. After a chain of reactions in mitochondria branched-chain α-keto acids will be transformed to derives of CoA, e.g. Acetyl-CoA and Succinyl-CoA, which can participate into other metabolic pathways such as citrate cycle. If the function of the enzyme complex BCKDC is disturbed like in MSUD, the amino acids and their metabolites (BCKAs) can't be removed and accumulate in blood and tissue. Accumulation of BCKAs results in a ketoacidose, i. e. the pH value of the blood decreases, which explains some of the symptoms described in #Phenotype.

Branched-chain α-keto acids dehydrogenase complex

The branched-chain α-keto acids dehydrogenase complex (BCKDC) is the main catalysator for the degradation of BCAAs in mitochondrial matrix. It has three component enzymes with different catalytic activities (genes are given in braces):

• E1: alpha-keto acid dehydrogenase (alpha chain BCKDHA, beta chain BCKDHB)
• E2: dihydrolipoyl transacylase (DBT)
• E3: dyhydroliponamide dehydrogenase (DLD)

Cross-references

• MSUD entry in KEGG
• leucine entry in KEGG
• valine, leucine and isoleucine degradation pathway in KEGG
• MetaCyc reaction

Genetics of pathognesis

Mutations

For each of the four genes BCKDHA, BCKDHB, DBT and DLD that produce subunits of BCKDC mutations are found among the population.

Reported mutations according to HGMD

Gene	Mutations
BCKDHA	65
BCKDHB	65
DBT	53
DLD	17

Reference sequence

Which sequence does not cause the disease and is most often found in the population.

• Reference sequence of BCKDHA
• Reference sequence of BCKDHB
• Reference sequence of DBT
• Reference sequence of DLD

Neutral mutations

These reported mutations are neutral and do not alter the protein during translation.

• Neutral mutations in BCKDHA
• Neutral mutations in BCKDHB
• Neutral mutations in DBT
• Neutral mutations in DLD

Disease causing mutations

Following mutations in the corresponding gene can result into functional changes of BCKDC and thus lead to MSUD.

• Disease causing mutations in BCKDHA
• Disease causing mutations in BCKDHB
• Disease causing mutations in DBT
• Disease causing mutations in DLD

Diagnosis

For a diagnosis of MSUD at first the above mentioned symptoms have to be present. The enzyme activity of the BCKDC can be measured and compared to the normal activity. With HPLC or mass spectrometry the accumulation of BCAAs, allo-isoleucine and BCKAs in the plasma can be measured. BCKAs in the urine are detected with dinitrophenylhydrazine (DNPH), which forms a precipitate with these compounds. To confirm the diagnosis, the genes encoding BCKDC subunits can be sequenced for mutations.

Treatment

To normalize the levels of amino acids and alpha-keto acids a special, almost protein free, diet with low levels of BCAAs is given. To avoid deficits in other nutrients there exist formulas for MSUD which are free of BCAAs. The blood of affected patients is frequently tested and BCAA concentrations are carefully monitored so that the brain is not damaged.

References

http://en.wikipedia.org/wiki/Maple_syrup_urine_disease
http://de.wikipedia.org/wiki/Ahornsirupkrankheit
http://www.pdb.org/
http://www.omim.org/entry/248600
http://www.hgmd.cf.ac.uk/ac/index.php
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001411/
http://www.ncbi.nlm.nih.gov/books/NBK1319/
http://www.ebi.ac.uk/chebi
http://www.genome.jp/kegg/disease/
http://metacyc.org/